Unusual imaging of pancreatic metastasis: A case report of tumor-to-tumor metastasis

Rossella Graziani, Paola Spaggiari, Silvia Carrara, Giovanna Lo Bue, Alessandro Zerbi, Luca Balzarini

ABSTRACT

Introduction: Metastasis of one tumor to another tumor is a very rare and controversial phenomenon. Solitary renal cell carcinoma metastasis to a preexisting pancreatic endocrine tumor is distinctly uncommon. We report atypical imaging findings of pancreatic metastasis from renal cell carcinoma, due to tumor-to-tumor metastasis for presence of renal cell carcinoma metastasizing to a pancreatic endocrine tumor.

Case Report: A 78-year-old male suffering from mild anemia underwent to multidetector computed tomography scan showing renal cell carcinoma and solid-cystic pancreatic mass, both resectable, treated with right radical nephrectomy and spleno-distal pancreatectomy. Histopathology of the resected renal and pancreatic specimens confirmed a clear cells right renal cell carcinoma metastatic to endocrine neoplasm of pancreatic body-tail. We compared multidetector computed tomography scan findings and histopathological pancreatic specimen. The imaging finding of peripheral rim enhancement coincided in pancreatic pathologic specimen with presence of pancreatic endocrine tumor. The imaging finding of solid trabeculae inside the mass corresponded in pancreatic pathologic specimen to presence of pancreatic endocrine tumor mixed with lobules of typical renal carcinoma metastatic cells. Finally, the imaging finding of hypoenhancing central area of lesion coincided in pancreatic pathologic specimen with presence of large necrotic component.

Conclusion: We describe an unusual multidetector computed tomography scan finding of renal cell carcinoma metastasizing to pancreatic endocrine tumor and emphasize the knowledge of rare phenomena of tumor-to-tumor metastasis.
Unusual imaging of pancreatic metastasis: A case report of tumor-to-tumor metastasis

Rossella Graziani, Paola Spaggiari, Silvia Carrara, Giovanna Lo Bue, Alessandro Zerbi, Luca Balzarini

ABSTRACT

Introduction: Metastasis of one tumor to another tumor is a very rare and controversial phenomenon. Solitary renal cell carcinoma metastasis to a preexisting pancreatic endocrine tumor is distinctly uncommon. We report atypical imaging findings of pancreatic metastasis from renal cell carcinoma, due to tumor-to-tumor metastasis for presence of renal cell carcinoma metastasizing to a pancreatic endocrine tumor. Case Report: A 78-year-old male suffering from mild anemia underwent to multidetector computed tomography scan showing renal cell carcinoma and solid-cystic pancreatic mass, both resectable, treated with right radical nephrectomy and spleno-distal pancreatectomy. Histopathology of the resected renal and pancreatic specimens confirmed a clear cells right renal cell carcinoma metastatic to endocrine neoplasm of pancreatic body-tail. We compared multidetector computed tomography scan findings and histopathological pancreatic specimen. The imaging finding of peripheral rim enhancement coincided in pancreatic pathologic specimen with presence of pancreatic endocrine tumor. The imaging finding of solid trabeculae inside the mass corresponded in pancreatic pathologic specimen to presence of pancreatic endocrine tumor mixed with lobules of typical renal carcinoma metastatic cells. Finally, the imaging finding of hypoenhancing central area of lesion coincided in pancreatic pathologic specimen with presence of large necrotic component. Conclusion: We describe an unusual multidetector computed tomography scan finding of renal cell carcinoma metastasizing to pancreatic endocrine tumor and emphasize the knowledge of rare phenomena of tumor-to-tumor metastasis.

Keywords: Tumor-to-tumor metastasis, Pancreatic Endocrine Tumor, Renal cell carcinoma, Pancreatic metastasis

INTRODUCTION

Renal cell carcinoma (RCC) metastases to the pancreas is especially rare. Their incidence in autopsy series has been reported as 1–3% in patients with primary RCC and their diagnosis is often radiological [1]. Early detection of RCC pancreatic metastases, frequently performed by multidetector computed tomography (MDCT) due to the imaging pattern of hyperenhancing lesions allows for appropriate treatment and improved outcomes for metastatic disease [2–4].

Metastasis of one tumor to another tumor is a very rare phenomenon in which one tumor metastasizes into another tumor [5].
The aim of this case report is to describe atypical MDCT picture of pancreatic metastasis from RCC due to pancreatic endocrine tumor (PET) metastasized by renal cell carcinoma. We emphasize the knowledge of this rare phenomenon in order to avoid an incorrect imaging diagnosis and to planning a relevant treatment.

CASE REPORT

Asymptomatic 78-year-old male, non-smoker and non-drinker, with unremarkable past surgical history, was admitted to our hospital for occasional finding at check-up laboratory tests of persistent iron deficiency mild anemia during the last six months and ultrasound detection of pancreatic and renal masses. The physical examination was noncontributory.

Laboratory investigations on admission showed a normal white blood cells count 10.0x10^9/L (reference range: 4.0–11.0x10^9/L) and a reduced serum level of hemoglobin 11.8 g/dL (reference range: 12–16 g/dL). His serum levels of lipase, amylase, CA19-9, liver enzymes and renal function tests were within the normal range. Moderate increased blood level of endocrine tumor markers was present with Chromogranin A of 115.87 U/L (reference range: 19–98 U/L) and NSE of 14.73 ng/mL (normal value inferior to 12.5 ng/mL).

A 64-slice MDCT scan examination with quadriphasic study (pre-contrast enhanced, contrast enhanced pancreatic, venous and delayed phases) was performed. A contrast enhanced MDCT scan showed focal enlargement of pancreatic body due to the presence of large solid-cystic mass (Figure 1), well-delimited but not encapsulated, measuring 80 mm in maximum diameter, mainly solid with some irregular, large, low-density central areas, suggesting presence of necrosis, and solid trabeculae inside central areas, hypotenuating before contrast medium administration (Figure 1A). A thin peripheral rim enhancement was present during the pancreatic phase of contrast enhanced MDCT study (Figure 1D), showing wash-out in venous (Figure 1E) and late (Figure 1F) phases. The central areas and solid trabeculae of this mass remained hypoenhanced (Figure 1E–F) during all phases of MDCT study. The dilatation of upstream main pancreatic duct associated to parenchyma atrophy (Figure 1C) was present. There was no evidence of local invasion and peripancreatic vessels were preserved.

Figure 1(A–F): Multidetector computed tomography imaging. Pre-contrast (A) and contrast-enhanced pancreatic (A–D), venous (E) and late (F) phases. Axial images. Multi-detector computed tomography examination showed a pancreatic body well-delimited mass (A, C–F) with maximum diameter of 80 mm, a peripheral rim enhancement (arrow), irregular low-density central areas and solid trabeculae (arrowhead), both hypoenhanced compared to the unaffected parenchyma of pancreatic tail (B) in pancreatic phase (C–D). During the portal venous (E) and delayed (F) phases, the mass remained hypodense and peripheral rim of enhancement showed wash-out. The upstream main pancreatic duct was dilated (C). Perinodular solid masses (short arrow) bulging from the upper pole of right kidney with maximum diameter of 70 mm, homogeneously hyperenhancing during pancreatic phase (B–D) with wash-out during venous (E) and late (F) phases of examination were visible. There was no evidence of local peripancreatic and perirenal invasion, liver metastasis. Superior mesenteric, splenic vessels, portal vein, and renal vessels were preserved.
A multinodular solid mass bulging from the upper pole of right kidney with maximum diameter of 60 mm was visible (Figure 1). This renal lesion was homogeneously hyperenhancing during pancreatic phase of examination (Figure 1B-D), showing wash-out during venous (Figure 1E) and late (Figure 1F) phases of MDCT study. Extra-renal involvement was absent and right renal vessels were preserved.

There was no evidence of abdominal lymphadenopathy, free fluid or metastatic lesions in the liver and in left kidney. Computed tomography scan of the chest was normal.

Endoscopic ultrasound (EUS) confirmed the presence of a well-demarcated solid-cystic mass of pancreatic body, hypoechoic with central fluid and hyperechoic areas, indicating intratumoral necrosis or hemorrhage (Figure 2A). Fine-needle aspiration biopsy endoscopic ultrasound guided (EUS-FNAB) of pancreatic lesion, performed using a 22-gauge needle (Figure 2B) revealed presence of malignant cells. Fine-needle aspiration ultrasound guided of one lesion bulging from the right renal upper pole revealed presence of malignant cells of RCC.

The imaging findings were suggestive for presence of right kidney RCC associated with primary malignant lesion of pancreatic body without usual imaging pattern of pancreatic metastasis form renal cancer. All renal and pancreatic lesions were resectable. The patients underwent right radical nephrectomy and distal pancreatectomy. On gross pathologic examination, in the pancreatic specimen of resected body-tail, a well-circumscribed red and yellow variegated lesion measuring 6 cm in the greatest dimension was present. The lymph nodes identified separately were free of cancer, and the spleen was unremarkable.

Histology of the pancreatic lesion showed two different cells population. In peripheral portion of the mass (Figure 3A) pancreatic endocrine tumor (PET) cells were exclusively observed, infiltrating even solid trabeculae inside pancreatic lesion, mixed with lobules of RCC composed of clear cells (Figure 3C). Immunohistochemistry confirmed the histologic picture: CD10 immunoperoxidase showed staining of RCC with no uptake of stain by PEN and synaptophysin immunoperoxidase of an adjacent section demonstrated of PEN only (Figure 3D), which was also positive at Chromogranin A and CD56 staining. PET resulted NET G1 according to WHO classification (2010), with Ki 67 of 1% and pT2N0 according TNM stage. This histological picture can be entirely consistent with a pancreatic endocrine neoplasm surrounding a well-defined nodule of metastatic renal cell carcinoma.

On gross pathologic examination, in the renal specimen of resected right kidney a multinodular, circumscribed and exophytic lesion measuring 7 cm in the greatest dimension was present in the upper pole. Histopathology of the resected renal specimen confirmed a renal cell carcinoma of the kidney, composed mainly of clear cells. The TNM stage was pT3b, pNx, pM1. Adjuvant therapy were recommended after surgery but the patient declined.

Follow-up with physical examination, laboratory tests, thoracic and abdominal MDCT scan were done every six months.

The patient remain without evidence of disease 12 months from the original diagnosis.
DISCUSSION

Metastasis of one tumor to another tumor is a very rare phenomenon. The criteria for satisfying a true tumor-to-tumor metastasis are as follows [5, 6]:

1. more than one tumor must exist
2. the recipient tumor is a true neoplasm
3. the metastatic neoplasm is a true metastasis with established growth in the host tumor and not the result of contiguous growth
4. tumors that have metastasized to the lymphatic system where lymphoreticular malignant tumors already exist are excluded.

This case report showed two distinct neoplasms and histologic evidence of encasement of an RCC by a PET. The comprehensive criteria that must be fulfilled for the diagnosis of a true tumor-to-tumor metastasis were present in our patient.

Several authors have reported in literature lung cancer is the most common donor tumor, whereas RCC is the most common recipient [5–9]. The reason for tumor-to-tumor metastasis favoring specific tumors is still unknown. The RCC’s rich vascularity, high content of glycogen and lipid, tendency to be localized without infiltration or metastasis could explain its favorable environment for receiving metastases from other cancers [6, 7, 9].

A solitary RCC metastasis to a preexisting pancreatic endocrine tumor (PET) is very uncommon. It is known in literature that PET are frequently hypervascular neoplasms.

Matsukuma investigating 47 autopsy cases of lung cancer concomitant with other tumors found tumor-to-tumor metastasis in only one pancreatic endocrine microadenoma [7].

Cenkowski first described one case of RCC metastasizing to a preexisting PET, reporting MDCT and histopathologic findings [10].

In both cases, reported by Cenkowski and in our patient, MDCT findings of pancreatic lesion due to tumor-to-tumor metastasis from RCC are different from MDCT typical picture of pancreatic metastasis from RCC, which appears as enhancing lesions [1, 2], reflecting hypervascularity of the of primary tumor.

We found a well-delimited solid-cystic mass, with MDCT peripheral rim enhancement, low-density central areas and solid trabeculae, both hypoenhancing after contrast medium administration during pancreatic phase of MDCT study.

We assessed MDCT imaging findings and histopathological pancreatic specimen, comparing them. We have found that MDCT imaging finding of peripheral rim enhancement coincided in pancreatic pathologic specimen with presence of pancreatic endocrine tumor. The imaging finding of solid trabeculae inside the mass corresponded in pathologic specimen to the presence of pancreatic endocrine tumor mixed with lobules of typical renal carcinoma metastatic cells. Finally, the MDCT finding of hypoenhancing central area of lesion coincided in pathologic specimen with presence of large necrotic component.

Early detection of metastases to the pancreas allows for appropriate treatment and improved outcomes of disease. In patients with pancreatic metastases from RCC, absence of extrapancreatic metastases and limited vascular involvement, 2 and 5 years survival rates of 78% and 65%, respectively after resection of pancreatic disease are reported [3, 4]. In our patients, radical nephrectomy and distal pancreatectomy were performed without complications. Clinical, laboratory, imaging follow-up after one year are all negative. However, the true prognosis of tumor-to-tumor metastasis remains unknown because this phenomenon is rare and most of the articles in literature about this disease are sporadic cases reports.

CONCLUSION

A knowledge of rare phenomenon of RCC metastasizing to a preexisting pancreatic endocrine tumor is useful to avoid an incorrect diagnosis in the presence of unusual imaging findings in the pancreatic metastasis from renal cancer. On the basis of these reports, the mechanisms for RCC to pancreatic endocrine tumor specific metastasis, as well as correct treatment and prognosis of this rare disease may be elucidated in the future.

*********

Author Contributions

Rossella Graziani – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Paola Spaggiari – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Silvia Carrara – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Giovanna Lo Bue – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Alessandro Zerbi – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Luca Balzarini – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.
Graziani et al. 770

SUGGESTED READINGS

- Jackson JG, Symmers WSC. Coexistence at one site of two neoplasms, one of local origin and one metastatic. Brit J Cancer 1951;5:38–44.

ABOUT THE AUTHORS


Rossella Graziani is Radiology MD Consultant in Imaging of Abdominal and Pancreatic - Biliary Disease in Humanitas Clinical Research Hospital, Milan, Italy. She was Director of Radiology Department (Body Section) at Poliambulanza Hospital in Brescia and worked for many years in Department of Radiology of Verona University, center of excellence for Italian pancreatic pathology. Her clinical interests include imaging of all pancreatic diseases. She is the author of many papers about imaging of pancreatic disease published in international journals and of monographic book on Multi-detector computed tomography of the pancreas, published by Idelson - Gnocchi in 2008. Email: Rossella.paola.graziani@gmail.com

International Journal of Case Reports and Images, Vol. 5 No. 11, November 2014. ISSN – [0976-3198]
<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
<th>Hospital and Location</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paola Spaggiari</td>
<td>Department of Pathology</td>
<td>Humanitas Clinical Research</td>
<td><a href="mailto:paola.spaggiari@humanitas.it">paola.spaggiari@humanitas.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital, Rozzano (Milan), Italy</td>
<td></td>
</tr>
<tr>
<td>Silvia Carrara</td>
<td>Department of Gastroenterology and Digestive Endoscopy</td>
<td>Humanitas Clinical Research Hospital, Rozzano (Milan), Italy</td>
<td></td>
</tr>
<tr>
<td>Giovanna Lo Bue</td>
<td>Department of Radiology</td>
<td>Humanitas Clinical Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital, Rozzano (Milan), Italy</td>
<td></td>
</tr>
<tr>
<td>Alessandro Zerbi</td>
<td>Department of Surgery</td>
<td>Humanitas Clinical Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital, Rozzano (Milan), Italy</td>
<td></td>
</tr>
<tr>
<td>Luca Balzarini</td>
<td>Department of Radiology</td>
<td>Humanitas Clinical Research</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hospital, Rozzano (Milan), Italy</td>
<td></td>
</tr>
</tbody>
</table>
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals